About this episode
You’ve heard about Chinese EVs. You’ve heard about Chinese batteries and solar panels. And recently you learned that China is near the cutting edge of AI research. Here’s another category: biotech. In 2019, the Chinese share of molecules licensed to Big Pharma companies was 0%. In 2024, it’s now 31%. On this episode we speak with Tim Opler, a biotech industry investment banker at Stifel. He explains how this industry has taken off in such a short period of time. Among the factors he cites: a generation of Chinese research scientists working in the US who hit a ceiling in terms of promotion and thus went back home to start companies. It’s also far cheaper to run clinical trials in China, due to the structure of the healthcare system. We also talk about the broad history of the pharmaceutical industry, how it’s evolved, and what impact, if any, AI will have on drug discovery.
Read More:
Former J&J Scientist Bets on China Biotech
Chinese Health Stocks Surge on DeepSeek Integration Potential
Odd Lots is coming to Washington, DC! Get your tickets for our Jones Act debate here.
See omnystudio.com/listener for privacy information.
Get every episode summarized
Each time Odd Lots publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Odd Lots
Why Laser Beams Are the Hottest New Tech in Defense
Odd Lots
What's Behind the Big Surge in US Government Bond Yields
Odd Lots
Adam Posen Thinks Things Could Get Very 'Messy' for the Fed
Odd Lots
Richmond Fed’s Tom Barkin on the Surprisingly Resilient Real Economy
Odd Lots